IMM-529

IMM-529 is an oral polyclonal antibody therapy developed to target and neutralize the main virulence factors of *Clostridioides difficile* (C. difficile), specifically for the prevention and treatment of recurrent C. difficile infection (CDI). The drug contains bovine colostrum-derived antibodies generated by immunizing dairy cows, resulting in hyperimmune bovine colostrum that targets three essential components of C. difficile pathogenesis: Toxin B, spores, and surface layer proteins of vegetative cells[1][3][5][6]. This triple-target approach aims to neutralize Toxin B locally in the gut while binding spores and vegetative cells to prevent colonization and recurrence without disrupting the normal gut microbiome[5][6]. Preclinical studies have shown efficacy in preventing primary disease, protecting against recurrence, and treating active infection[3][7]. IMM-529 is being developed as an adjunctive therapy alongside standard-of-care antibiotics for CDI[3]. The developer is Immuron, an Australian biopharmaceutical company; manufacturing has involved CSIRO Agriculture and Food as well as collaboration with Monash University for vaccine manufacture support[5].

Other names

IMM 529IMM529IMM-529